Whalesbook
Deal ki Kahani Kya Hai?
Indoco Remedies ne Sunways (India) Private Limited ke saath ek deal finalize ki hai jismein woh apna domestic ophthalmic division aur kuch African territories mein related operations ko ₹110 crore mein sell kar rahe hain. Yeh sale ek slump sale ke taur par ho rahi hai aur ummeed hai ki sabhi approvals milne ke baad yeh transaction lagbhag teen mahine mein poori ho jayegi. Buyer, Sunways, jo ki 1953 se eyecare sector mein hai, FY25 mein ₹137.42 crore ka standalone revenue generate kar chuki hai.
Ophthalmic Unit Ka Kitna Contribution Tha?
Indoco ke liye yeh ophthalmic unit FY25 mein Rs 47.79 crore ka revenue generate kar raha tha, jo ki company ke total standalone revenue ka sirf 3.2% tha. Market ne bhi is deal par koi khaas reaction nahi dikhaya, aur stock 0.072% girkar ₹209.05 par band hua, jo batata hai ki investors is unit ko itna 'core' nahi maante.
Company Ki Financial Situation:
Asal mein, Indoco Remedies pichle kuch samay se financial challenges face kar rahi hai. Company ne lagbhag chaar quarters se net losses report kiye hain, jismein Q3 FY26 mein hi ₹29.79 crore ka loss hua tha. December 2025 tak, company ka trailing twelve-month revenue lagbhag ₹1,630 crore ($197 million) tha aur net loss ₹1,070 crore ($13 million) ke aas-paas tha. Debt bhi kaafi badh gaya hai, jo March 2025 tak ₹900 crore se ₹960 crore ho gaya tha, jabki company ka market cap lagbhag ₹1,900-₹1,950 crore tha. Is high leverage aur declining revenues ki wajah se ICRA ne January 2025 mein company ki credit rating ko [ICRA]A+ (Negative)/[ICRA]A1 kar diya tha.
Aage Kya Ho Sakta Hai?
Is sale se jo ₹110 crore milenge, woh company apne operations improve karne, debt kam karne ya zyada profitable areas mein invest karne ke liye use karegi. Investors ab Q4 FY26 results ka wait kar rahe hain, jo May 2026 mein aane wale hain, yeh dekhne ke liye ki company FY27 ke liye kya outlook deti hai. Indian pharma sector growth mein hai, lekin Indoco ka standalone performance FY2025 mein 14.60% revenue decline ke saath lagging raha hai. Analysts ka consensus 'HOLD' rating hai, aur kuch ne downgrades bhi kiye hain, matlab abhi caution barqatna zaroori hai.